All In Biotech

NDA 205175 · Resilia Pharms

Ecoza

Econazole Nitrate · Topical

Last checked: Nov 19, 2026Latest source record: Nov 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Oct 24, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

3 Phase 3, 0 recruiting

FAERS reports

947

615 serious, 57 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2025.

Econazole nitrate topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. Econazole nitrate is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes , and Epidermophyton floccosum in patients 12 years of age and older. ( 1 )

Mechanism: Econazole nitrate topical foam is an azole antifungal [ see Clinical Pharmacology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ECOZA · ECONAZOLE NITRATE 1% · AEROSOL, FOAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Econazole Nitrate" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue63
  • drug ineffective59
  • rash50
  • dyspnoea48
  • nausea48
  • pain47
  • diarrhoea45
  • dizziness41
  • asthenia39
  • headache39
  • pruritus39
  • renal failure38

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20059
200613
200719
200821
200928
201018
201134
201233
201335
201415
201562
201664
201774
201879
201964
202073
202148
202240
202353
202449
202557
202651

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Resilia Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.